PURPOSE: Silent myocardial ischaemia--as evaluated by stress-induced perfusion defects on myocardial perfusion scintigraphy (MPS) in patients without a history of chest pain--is frequent in diabetes and is associated with increased rates of cardiovascular events. Its prevalence has been determined in asymptomatic diabetic patients, but remains largely unknown in diabetic patients with suspected coronary artery disease (CAD) in the clinical setting. In this study we therefore sought (a) to determine the prevalence of symptomatic and silent perfusion defects in diabetic patients with suspected CAD and (b) to characterise the eventual predictors of abnormal perfusion. METHODS: The patient population comprised 133 consecutive diabetic patients with suspected CAD who had been referred for MPS. Studies were performed with exercise (41%) or pharmacological stress testing (1-day protocol, (99m)Tc-sestamibi, 201Tl or both). We used semi-quantitative analysis (20-segment polar maps) to derive the summed stress score (SSS) and the summed difference score (SDS). RESULTS: Abnormal MPS (SSS> or =4) was observed in 49 (37%) patients (SSS=4.9+/-8.4, SDS=2.4+/-4.7), reversible perfusion defects (SDS> or =2) in 40 (30%) patients [SSS=13.3+/-10.9; SDS=8.0+/-5.6; 20% moderate to severe (SDS>4), 7% multivessel] and fixed defects in 21 (16%) patients. Results were comparable between patients with and patients without a history of chest pain. Of 75 patients without a history of chest pain, 23 (31%, 95% CI=21-42%) presented reversible defects (SSS=13.9+/-11.3; SDS=7.4+/-1.2), indicative of silent ischaemia. Reversible defects were associated with inducible ST segment depression during MPS stress [odds ratio (OR)=3.2, p<0.01). Fixed defects were associated with erectile dysfunction in males (OR=3.7, p=0.02) and lower aspirin use (OR=0.25, p=0.02). CONCLUSION: Silent stress-induced perfusion defects occurred in 31% of the patients, a rate similar to that in patients with a history of chest pain. MPS could identify these patients with a potentially increased risk of cardiovascular events.
PURPOSE:Silent myocardial ischaemia--as evaluated by stress-induced perfusion defects on myocardial perfusion scintigraphy (MPS) in patients without a history of chest pain--is frequent in diabetes and is associated with increased rates of cardiovascular events. Its prevalence has been determined in asymptomatic diabeticpatients, but remains largely unknown in diabeticpatients with suspected coronary artery disease (CAD) in the clinical setting. In this study we therefore sought (a) to determine the prevalence of symptomatic and silent perfusion defects in diabeticpatients with suspected CAD and (b) to characterise the eventual predictors of abnormal perfusion. METHODS: The patient population comprised 133 consecutive diabeticpatients with suspected CAD who had been referred for MPS. Studies were performed with exercise (41%) or pharmacological stress testing (1-day protocol, (99m)Tc-sestamibi, 201Tl or both). We used semi-quantitative analysis (20-segment polar maps) to derive the summed stress score (SSS) and the summed difference score (SDS). RESULTS:Abnormal MPS (SSS> or =4) was observed in 49 (37%) patients (SSS=4.9+/-8.4, SDS=2.4+/-4.7), reversible perfusion defects (SDS> or =2) in 40 (30%) patients [SSS=13.3+/-10.9; SDS=8.0+/-5.6; 20% moderate to severe (SDS>4), 7% multivessel] and fixed defects in 21 (16%) patients. Results were comparable between patients with and patients without a history of chest pain. Of 75 patients without a history of chest pain, 23 (31%, 95% CI=21-42%) presented reversible defects (SSS=13.9+/-11.3; SDS=7.4+/-1.2), indicative of silent ischaemia. Reversible defects were associated with inducible ST segment depression during MPS stress [odds ratio (OR)=3.2, p<0.01). Fixed defects were associated with erectile dysfunction in males (OR=3.7, p=0.02) and lower aspirin use (OR=0.25, p=0.02). CONCLUSION: Silent stress-induced perfusion defects occurred in 31% of the patients, a rate similar to that in patients with a history of chest pain. MPS could identify these patients with a potentially increased risk of cardiovascular events.
Authors: X Kang; D S Berman; H C Lewin; I Cohen; J D Friedman; G Germano; R Hachamovitch; L J Shaw Journal: Am Heart J Date: 1999-12 Impact factor: 4.749
Authors: G Vanzetto; S Halimi; T Hammoud; D Fagret; P Y Benhamou; D Cordonnier; B Denis; J Machecourt Journal: Diabetes Care Date: 1999-01 Impact factor: 19.112
Authors: P Valensi; R N Sachs; B Lormeau; J M Taupin; J Ouzan; A Blasco; A Nitenberg; D Metz; J Paries; O Talvard; M Leutenegger; J R Attali Journal: Diabetes Metab Date: 1997-11 Impact factor: 6.041
Authors: R Hachamovitch; D S Berman; L J Shaw; H Kiat; I Cohen; J A Cabico; J Friedman; G A Diamond Journal: Circulation Date: 1998-02-17 Impact factor: 29.690
Authors: D S Berman; H Kiat; J D Friedman; F P Wang; K van Train; L Matzer; J Maddahi; G Germano Journal: J Am Coll Cardiol Date: 1993-11-01 Impact factor: 24.094
Authors: S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel Journal: Eur J Nucl Med Mol Imaging Date: 2004-02 Impact factor: 9.236
Authors: Arthur J H A Scholte; Joanne D Schuijf; Antje V Kharagjitsingh; Petra Dibbets-Schneider; Marcel P Stokkel; Ernst E van der Wall; Jeroen J Bax Journal: Eur J Nucl Med Mol Imaging Date: 2008-11-05 Impact factor: 9.236
Authors: Jacobijne J Wiersma; Hein J Verberne; Mieke D Trip; Wik L ten Holt; Berthe L F van Eck-Smit; Jan J Piek; Jan G P Tijssen Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-21 Impact factor: 10.057
Authors: Manoefris Kasim; Geoffrey M Currie; Markus Tjahjono; Bambang B Siswanto; Ganesja M Harimurti; Hosen Kiat Journal: Open Cardiovasc Med J Date: 2013-09-20
Authors: Dane K Wukich; David G Armstrong; Christopher E Attinger; Andrew J M Boulton; Patrick R Burns; Robert G Frykberg; Richard Hellman; Paul J Kim; Benjamin A Lipsky; James C Pile; Michael S Pinzur; Linda Siminerio Journal: Diabetes Care Date: 2013-09 Impact factor: 19.112